Ignite Creation Date:
2024-05-05 @ 9:08 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00828620
Status:
TERMINATED
Last Update Posted:
2012-08-10
First Post:
2009-01-23
Brief Title:
Positron Emission Tomography - Computed Tomography PET-CT Cetuximab Project
Sponsor:
Universitaire Ziekenhuizen KU Leuven
Organization:
Universitaire Ziekenhuizen KU Leuven
Study Overview
Official Title:
Imaging for Early Response Prediction to EGF-receptor Blocking Monoclonal Antibodies in Combination Therapy for Colorectal Cancer
Status:
TERMINATED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Molecular imaging with positron emission tomography PET using 18F fluorodeoxyglucose FDG has been suggested as an early sensitive marker of tumour response to anticancer drugs by monitoring the changes in glucose metabolism in tumours Recently FDG-PET has shown to be highly sensitive in detecting early response in other tumours In this study the investigators will prospectively investigate the role of early FDG-PET at day 7 and week 6 in outcome prediction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None